Investor Alert

Teva Pharmaceutical Industries Ltd. ADR



After Hours

 --Quotes are delayed by 20 min

Sep 30, 2022, 7:51 p.m.





-0.01 -0.12%


Volume 236,713

Quotes are delayed by 20 min


Previous close

$ 7.82

$ 8.07


+0.25 +3.20%

Day low

Day high




52 week low

52 week high




Annual Financials for Teva Pharmaceutical Industries Ltd. ADR

Operating Activities

Fiscal year is January-December. All values ILS millions. 20172018201920202021 5-year trend
Net Income before Extraordinaries (59.17B)(8.89B)(3.57B)(14.1B)1.47B
Depreciation, Depletion & Amortization 7.6B6.62B6.14B5.35B4.3B
Depreciation and Depletion 2.27B2.43B2.17B1.85B1.71B
Amortization of Intangible Assets 5.32B4.19B3.97B3.51B2.59B
Deferred Taxes & Investment Tax Credit (8.38B)(3.01B)(3.51B)(2.39B)(387.61M)
Deferred Taxes (8.38B)(3.01B)(3.51B)(2.39B)(387.61M)
Investment Tax Credit -----
Other Funds 78.44B27.35B12B27.67B8.01B
Funds from Operations 18.48B22.07B11.06B16.54B13.4B
Extraordinaries -----
Changes in Working Capital (5.87B)(7.04B)(3.09B)(7.52B)(5.49B)
Receivables 1.85B316.38M(1.4B)(1.01B)(1.85B)
Accounts Payable (11.09B)(1.8B)2.29B(1.59B)2.47B
Other Assets/Liabilities 2.41B(5.65B)(4.95B)(5.07B)(7.34B)
Net Operating Cash Flow 12.61B15.03B7.96B9.01B7.9B

Investing Activities

20172018201920202021 5-year trend
Capital Expenditures (3.14B)(2.34B)(1.87B)(1.99B)(1.82B)
Capital Expenditures (Fixed Assets) (3.14B)(2.34B)(1.87B)(1.99B)(1.82B)
Capital Expenditures (Other Assets) -----
Net Assets from Acquisitions -----
Sale of Fixed Assets & Businesses 12.66B3.2B1.22B--
Purchase/Sale of Investments ----555.58M
Purchase of Investments -----
Sale/Maturity of Investments ----555.58M
Other Uses (1.73B)(427.84M)(28.5M)(189.15M)(151.82M)
Other Sources -39.55M206.65M312.95M1.01B
Net Investing Cash Flow 7.78B470.98M(470.32M)(1.86B)(403.77M)

Financing Activities

20172018201920202021 5-year trend
Cash Dividends Paid - Total (4.18B)(79.1M)(185.28M)--
Common Dividends (3.24B)(43.14M)---
Preferred Dividends (935.21M)(35.95M)(185.28M)--
Change in Capital Stock -----
Repurchase of Common & Preferred Stk. -----
Sale of Common & Preferred Stock -----
Proceeds from Stock Options -----
Other Proceeds from Sale of Stock -----
Issuance/Reduction of Debt, Net (16.1B)(11.76B)(6.64B)(6.47B)(7B)
Change in Current Debt (6.05B)(934.77M)(7.13M)(30.95M)(1.59B)
Change in Long-Term Debt (10.05B)(10.83B)(6.63B)(6.43B)(5.41B)
Issuance of Long-Term Debt 1.82B15.94B7.42B-16.07B
Reduction in Long-Term Debt (11.87B)(26.77B)(14.05B)(6.43B)(21.48B)
Other Funds (402.86M)(204.93M)(39.19M)(17.2M)(19.38M)
Other Uses (402.86M)(204.93M)(39.19M)(17.2M)(19.38M)
Other Sources -----
Net Financing Cash Flow (20.68B)(12.05B)(6.86B)(6.48B)(7.02B)
Exchange Rate Effect 194.24M(510.53M)57.01M27.51M(413.46M)
Miscellaneous Funds -----
Net Change in Cash (89.92M)2.94B687.66M694.68M67.83M
Free Cash Flow 9.47B12.69B6.09B7.03B6.09B
Link to MarketWatch's Slice.